

Karyopharm Therapeutics Inc.
Form 4
November 12, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Chione Ltd

2. Issuer Name **and** Ticker or Trading
Symbol
Karyopharm Therapeutics Inc.
[KPTI]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)
11/10/2014

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

SIMOU MENARDOU 8, RIA
COURT 8, OFFICE 101

(Street)

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
____ Form filed by One Reporting Person
X Form filed by More than One Reporting
Person

6015 LARNACA, G4

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount (A) or (D)	Price	
COMMON STOCK	11/10/2014		S		31,400	D \$ 42.6496 (1) (2)	9,719,583 (3) (4) (5) D
COMMON STOCK	11/10/2014		S		23,100	D \$ 43.7984 (1) (2)	9,696,483 (3) (4) (5) D
COMMON STOCK	11/10/2014		S		10,300	D \$ 44.7343 (1) (2)	9,686,183 (3) (4) (5) D
COMMON	11/10/2014		S		200	D \$ 45.49	9,685,983 D

Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

STOCK					(1) (2)	(3) (4) (5)	
COMMON STOCK	11/11/2014	S	54,100	D	\$ 42.5116 (1) (2)	9,631,883 (3) (4) (5)	D
COMMON STOCK	11/12/2014	S	38,800	D	\$ 42.2573 (1) (2)	9,593,083 (3) (4) (5)	D
COMMON STOCK	11/12/2014	S	6,200	D	\$ 43.1878 (1) (2)	9,586,883 (3) (4) (5)	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Chione Ltd SIMOU MENARDOU 8 RIA COURT 8, OFFICE 101 6015 LARNACA, G4	X
Czernik Marcin SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4	X

Hadjimichael Andreas
SIMOU MENARDOU 8,
RIA COURT 8, OFFICE 101
6015 LARNACA, G4

X

Hadjimichael Amalia
SIMOU MENARDOU 8,
RIA COURT 8, OFFICE 101
6015 LARNACA, G4

X

Smolokowski Wiaczeslaw
CHALET LENOTCHKA CH.DE BARNOUD
1885 CHESIERES
SWITZERLAND, G4 00000

X

Signatures

/s/ Chione Limited, by /s/ Simon Prisk, as attorney-in fact by power of attorney

11/12/2014

__Signature of Reporting Person

Date

/s/ Marcin Czernik, by /s/ Simon Prisk, as attorney-in fact by power of attorney

11/12/2014

__Signature of Reporting Person

Date

/s/ Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney

11/12/2014

__Signature of Reporting Person

Date

/s/ Amalia Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney

11/12/2014

__Signature of Reporting Person

Date

/s/ Wiaczeslaw Smolokowski, by /s/ Simon Prisk, as attorney-in fact by power of attorney

11/12/2014

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Except as otherwise noted, the prices reported in Column 4 are weighted average prices. The 31,400 shares referred to in the first row of Column 4 were sold at prices ranging from \$42.25 to \$43.24, inclusive. The 23,100 shares referred to in the second row of Column 4 were sold at prices ranging from \$43.255 to \$44.245, inclusive. The 10,300 shares referred to in the third row of Column 4 were sold at prices ranging from \$44.275 to \$45.14, inclusive. The 200 shares referred to in the fourth row of Column 4 were sold at the \$45.49 price indicated. The 54,100 shares referred to in the fifth row of Column 4 were sold at prices ranging from \$42.50 to \$42.77, inclusive. The 38,800 shares referred to in the sixth row of Column 4 were sold at prices ranging from \$42.00 to \$42.745, inclusive. The 6,200 shares referred to in the seventh row of Column 4 were sold at prices ranging from \$43.00 to \$43.71, inclusive.

(2) The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in this footnote.

(3) Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Amalia Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione.

Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

- (4) Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed, except, with respect to any person, to the extent of the pecuniary interest of such person in such securities.
- (5) Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Remarks:

Exhibit Index Exhibit 24.1 - Power of Attorney, dated February 12, 2014, made by Marcin Czernik and Chione Limited in favor of

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.